Issues relating to drug pricing proposals including implementation of the Inflation Reduction Act (P.L. 117-169); Rx oversight issues; PBM oversight issues; Issues related to budget reconciliation; Issues related to Most Favored Nation proposals; Issues related to the FTC.
2025 · 2nd Quarter (Apr 1 - June 30)
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Filed by AKIN GUMP STRAUSS HAUER & FELD.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 21, 2025
- Income
- $120,000.00
- Expenses
- Not reported
- Registrant
- AKIN GUMP STRAUSS HAUER & FELD
- Filing UUID
- 00e8e5b8-de94-40c2-9b69-c0733ba29ee2
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to IP protection; Market access issues related to PhRMA 232.
Issues related to patent reform legislation; H.R. 3160/S. 1553 - PREVAIL Act
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.